International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management


The experiences expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

This paper was guest edited by Bernard J. Gersh (Mayo Clinic, gersh.bernard@mayo.edu).

* Corresponding author. Tel: +41 44 255 9585, Fax: +41 44 255 4401, Email: christian.templin@usz.ch

† Deceased.

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
The clinical expert consensus statement on takotsubo syndrome (TTS) part II focuses on the diagnostic workup, outcome, and management. The recommendations are based on interpretation of the limited clinical trial data currently available and experience of international TTS experts. It summarizes the diagnostic approach, which may facilitate correct and timely diagnosis. Furthermore, the document covers areas where controversies still exist in risk stratification and management of TTS. Based on available data the document provides recommendations on optimal care of such patients for practising physicians.

Keywords  Takotsubo syndrome • Broken heart syndrome • Acute heart failure • Consensus statement • Diagnostic algorithm

Outline

Diagnostic workup .......................................................... 2048
Electrocardiogram .......................................................... 2048
ST-segment elevation ...................................................... 2049
T-wave inversion and QT interval prolongation ....................... 2049
Other electrocardiographic findings ..................................... 2050
InterTAK Diagnostic Score ................................................. 2050
Biomarkers ................................................................. 2051
Markers of myocardial necrosis ........................................... 2051
B-type natriuretic peptide and N-terminal prohormone of brain natriuretic peptide ..................................................... 2051
Other potential biomarkers ................................................ 2051
Imaging ........................................................................... 2051
Coronary angiography and ventriculography ............................ 2051
Echocardiography ............................................................ 2051
Cardiac computed tomography angiography ......................... 2052
Cardiac magnetic resonance imaging .................................... 2053
Cardiac nuclear imaging ..................................................... 2053
Perfusion imaging ............................................................. 2053
Metabolic imaging ............................................................ 2053
Sympathetic nervous imaging ............................................. 2053
Complications and outcomes ............................................ 2053
Arrhythmias ...................................................................... 2055
Ventricular arrhythmias ....................................................... 2055
Other cardiac arrhythmias ................................................ 2055
Recurrence ....................................................................... 2055
Therapeutic management .................................................... 2056
Pre-hospital treatment ......................................................... 2056
Acute treatment ............................................................... 2056
Long-term treatment ......................................................... 2057
Future directions ............................................................. 2058
Key questions ..................................................................... 2058
Prospective approaches ...................................................... 2058
References ........................................................................ 2058

Diagnostic workup

A diagnostic algorithm for takotsubo syndrome (TTS) is proposed by the expert committee (Figure 1). Patients presenting with ST-segment elevation should undergo urgent coronary angiography (CAG) with left ventriculography to exclude acute myocardial infarction (AMI). In patients with non ST-segment elevation the InterTAK Diagnostic Score can be considered. While an InterTAK Score <70 points suggests a low to intermediate probability of TTS, a score ≥70 indicates a high probability for the presence of TTS. Patients with a low probability should undergo CAG with left ventriculography, while in patients with a high score transthoracic echocardiography (TTE) should be considered. In the absence of a circumferential ballooning pattern CAG is recommended. In stable patients with circumferential ballooning pattern coronary computed tomography angiography (CCTA) is favoured to exclude coronary artery disease (CAD). In unstable patients, typical complications of TTS such as left ventricular outflow tract obstruction (LVOTO) should be determined with TTE and CAG to safely rule out AMI. In patients with normal coronaries on CCTA or CAG and typical ballooning patterns without ‘red flags’ of acute infectious myocarditis TTS is the most likely diagnosis and can be confirmed after follow-up echocardiography. In case of positive ‘red flags’ of acute infectious myocarditis cardiac magnetic resonance (CMR) should be performed to confirm the diagnosis.

Electrocardiogram

The initial electrocardiogram (ECG) is abnormal in most patients with TTS usually demonstrating ischaemic ST-segment elevation, T-wave inversion, or both.1,4 In the InterTAK Registry, ST-segment elevation was present in 44%, ST-segment depression in 8%, T-wave inversion in 41%, and left bundle branch block in 5%.2 As in acute coronary syndrome (ACS), the ECG in TTS demonstrates temporal evolution typically with resolution of initial ST-segment elevation (if present), followed by progressive T-wave inversion and QT interval prolongation.
over several days, with subsequent gradual resolution of T-wave inversion and QT interval prolongation over days to weeks.5–8 The initial and subsequent ECG findings are influenced by several variables, including the geographic pattern of left ventricular (LV) ballooning, presence or absence of right ventricular (RV) ballooning, time from symptom onset to presentation, presence of myocardial oedema, and recovery rate of myocardial cellular function.

**ST-segment elevation**

As with ST-segment elevation myocardial infarction (STEMI), the location and extent of ST-segment elevation in TTS corresponds to the anatomic location of myocardial injury, most often the mid and apical LV segments.2 Consequently, ST-segment elevation usually involves precordial, lateral, and apical ECG leads, closely resembling that of anterior STEMI due to left anterior descending coronary occlusion.9,10 Lead aVR (inverse of aVR) representing +30° in the frontal plane is generally aligned with the LV apex, and can be assembled with other leads to create an ‘ECG map’, useful in comparing the ST-segment elevation pattern of TTS with that of anterior STEMI.1,3,11–12 ST-segment elevation in TTS is centred on precordial leads V2–V5 and limb leads II and aVR, whereas in anterior STEMI the ST-segment elevation centres on precordial leads V1–V4 and limb leads I and aVL. Several ECG criteria with high sensitivity and specificity have been proposed to reliably distinguish TTS from anterior STEMI.3,12–14 Most focus on ST-segment elevation in the precordial leads, particularly lead V1, as ST-segment elevation in this lead is less pronounced in TTS than in anterior STEMI.9,10,12 ST-segment elevation limited to the inferior leads (II, III, aVF) is distinctly uncommon in TTS. Despite these differences, overlap exists and an urgent coronary angiogram is necessary to differentiate TTS from STEMI with certainty.9–11

**T-wave inversion and QT interval prolongation**

Progressive T-wave inversion and QT interval prolongation is a common ECG finding in TTS. In patients with delayed presentation, these
changes may be present on admission in the absence of ST-segment elevation, and can be the only detectable ECG changes and therefore important for the diagnosis. The geographic distribution of T-wave inversion closely parallels that of ST-segment elevation and may be an electrophysiological manifestation of myocardial stunning. In TTS, T-wave inversion is often more prominent and more broadly distributed than in ACS. Furthermore, T-wave inversion is associated with presence of myocardial oedema, and may persist for several months even after LV contractile recovery, thus leaving an electrophysiological footprint of the TTS event. QT interval prolongation provides a substrate for torsades de pointes ventricular tachycardia and may be a prognostic marker for sudden cardiac death.

Other electrocardiogram findings
Anterior Q-waves (or poor R-wave progression) without accompanying ST-segment elevation or T-wave inversion, a pattern sometimes referred to as ‘anterior infarction, age indeterminate’ occurs with some frequency in TTS. Pathologic Q-waves are less frequently encountered in TTS than anterior STEMI (15% vs. 69%). In TTS, as in anterior STEMI, Q-waves may occur in the acute phase, and regress rapidly with R-wave re-appearance, consistent with electrical stunning. Both J-wave and/or fragmented QRS complexes have been reported acutely, the former associated with death from cardiac causes and/or ventricular tachyarrhythmia. Low QRS voltage likely representing myocardial oedema is prevalent in TTS. Left bundle branch block is present in around 5% of patients. ST-segment depression is uncommon, occurring in fewer than 10% of TTS patients but in over 30% of ACS patients, therefore, the presence of ST-segment depression may suggest ACS.

InterTAK Diagnostic Score
The InterTAK Diagnostic Score was developed by the International Takotsubo Registry to provide clinicians a model to assess the likelihood of TTS diagnosis. The criteria that make up the InterTAK Diagnostic Score are based on clinical features and ECG to predict the probability of the presence of TTS and to distinguish TTS from ACS. The InterTAK Diagnostic Score comprises seven parameters [female sex, emotional trigger, physical trigger, absence of ST-segment depression, psychiatric disorders, neurologic disorders, and QTc prolongation] ranked by their diagnostic importance with a maximum attainable score of 100 points. Depending on the disease prevalence this means that patients with 30 score points have a predicted probability of <1%, while patients with 50 points have a probability of 18%, and patients with a score value >70 points have a probability of ~90% of suffering from TTS.
Biomarkers

Markers of myocardial necrosis

Virtually all cases of TTS exhibit evidence of myocardial necrosis. On admission, troponin values are usually equally elevated compared to ACS, however, peak values are substantially lower compared to the classical ACS. High admission troponin levels are a predictor for a worse in-hospital outcome. Typically, there is only a slight increase in creatine kinase. The extent of LV regional wall motion impairment generally greatly exceeds that of associated myocardial necrosis biomarkers, likely reflecting a large mass of reversibly injured (stunned) myocardium.

B-type natriuretic peptide and N-terminal prohormone of brain natriuretic peptide

Takotsubo syndrome is frequently associated with a substantial increase in the plasma levels of B-type natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) reaching its peak approximately 24–48 h after symptom onset as a reflection of regional LV dysfunction. A gradual return of BNP/NT-proBNP towards normal levels occurs within the next few months after presentation.

The degree of NT-proBNP elevation appears directly related to: (i) the degree of sympathetic overactivation (as reflected by normetanephrine concentrations), (ii) peak C-reactive protein concentrations (suggesting that BNP release might be at least in part of inflammatory origin), and (iii) systolic LV dysfunction [as measured by wall motion score index (WMSI)]. Peak NT-proBNP levels also vary with the extent of LV oedema as measured by CMR.

Other potential biomarkers

Interleukin (IL)-6 levels appear less elevated while those of IL-7 are more elevated in TTS compared with AMI. However, differences between groups were small and unlikely to be of diagnostic utility.

Two recently published studies focused on the potential utility of the release and circulation of certain microRNAs (miRNAs) in association with TTS onset. Kuwabara et al. noted that elevation of circulating miR-133a appeared to represent an early consequence of myocardial injury, including TTS and AMI. However, subsequent analyses of cases of TTS (N = 36) and evolving STEMI (N = 27) suggested that the elevation of miR-133a was more marked in STEMI than in TTS. Furthermore, Jaguszewski et al. demonstrated that a unique signature including miR-1, miR-16, miR-26a, and miR-133a represents a robust biomarker on admission and can be used to differentiate TTS from STEMI patients. Furthermore, the up-regulation of miR-16 and miR-26a is known to be associated with stress- and affective disorders.

Especially in patients with biventricular involvement, it has been shown that plasma concentrations of the stress-responsive cytokine growth differentiation factor-15 increased more rapidly after the onset of TTS.

Imaging

Coronary angiography and ventriculography

Although non-invasive imaging modalities are useful in the workup of patients with TTS, final differential diagnosis from ACS requires coronary angiogram, which is performed in the context of ST-elevation in primary percutaneous coronary intervention service. In case of suspected TTS with coexisting and significant CAD, careful comparison of CAG and biplane ventriculography in similar views is mandatory to search for a perfusion-contraction mismatch. This comparison is essential for distinguishing TTS from classical AMI in patients with wall motion abnormalities and obstructive CAD. In this regard, it has been reported that approximately one-third of patients with the classical apical ballooning show a small zone with preserved contractility in the most distal portion of the apex, which is described as the ‘apical nipple sign’. Furthermore, as LVOTO occurs in approximately 20% of patients with TTS, haemodynamic assessment for the presence of a pressure-gradient in the outflow tract as well as assessment of left ventricular end-diastolic pressure are recommended. Figure 3A demonstrates apical ballooning pattern on left ventriculography.

Echocardiography

Echocardiography is the most used imaging tool to assess changes in LV function such as symmetric regional wall motion abnormalities (RWMA). Different variants can be identified with echocardiography which include:

1. Apical ballooning, hypo-, a-, or dyskinesia of mid-apical myocardial segments is typical, sometimes associated with hypokinetic mid-segments. The anterior or entire interventricular septum, inferior or midventricular anterolateral wall may also be involved.
2. Midventricular TTS featured by hypo-, a-, or dyskinesia of midventricular segments, most often resembling a cuff.
3. Basal forms where only basal segments are involved. This phenotype is rare and appears commonly in patients with subarachnoid haemorrhage, epinephrine-induced TTS or phaeochromocytoma.
4. Focal TTS mostly involving an anterolateral segment has been described. Differentiating this unusual TTS type from ACS or myocarditis requires CMR.

Right ventricular involvement is characterized by RV dilatation with hypo- or akinesis of the free wall and apex in its isolated form.

In TTS, LV wall motion abnormalities extend beyond the distribution of a single coronary artery territory, therefore systolic dysfunction appears ‘circular’ at speckle-tracking echocardiography. A WMSI >1.75 with more than four dysfunctional segments identifies TTS with 83% sensitivity and 100% specificity. Doppler estimation of coronary artery flow ameliorates the diagnostic accuracy of wall motion abnormalities, whereas adenosine may lead to dramatic improvements of global and regional LV function.

Intravenous ultrasound contrast agents facilitate wall motion assessment especially at the apex and constitute a useful method especially in patients in whom CAG is not performed, mainly due to active bleeding or other comorbid conditions that may imbalance the risk-benefit ratio of CAG (see Cardiac computed tomography angiography section). Myocardial opacification is reduced within dysfunctional segments with the transmural perfusion defects being more evident early after TTS onset. Coronary flow reserve, assessed by transthoracic Doppler echocardiography, is reduced to 1.6–2.6 at the levels of the right and left coronary arteries and correlates with indices of LV systolic but not diastolic function. In contrast to ischaemic cardiomyopathy, myocardial contraction does not improve with low-dose dobutamine at the early stages. However, it has also been demonstrated that low dose dobutamine stress echocardiography improved
systolic left ventricular function by normalizing or improving the hypo-
kinetic segments.\textsuperscript{61} Moreover, in STEMI, viable myocardial segments
exhibit longitudinal shortening, while in TTS systolic lengthening (pas-
sive motion) is present initially and resolves at follow-up.\textsuperscript{62}
Importantly, echocardiography allows detection of all acute TTS
complications. In LV apical ballooning, basal segments are hyperkinetic
and may cause dynamic LVOTO,\textsuperscript{63} mainly in patients with pre-existing
septal bulge\textsuperscript{64} which further reduces stroke volume and is associated
with mitral regurgitation (MR) due to systolic anterior motion of the
mitral leaflet (Figure 3B).\textsuperscript{63,65} Severe MR may also result from leaflet
tethering by displacement or dysfunction of papillary muscles. Mitral re-
gurgitation is estimated to be present in 14–25\% of TTS patients.\textsuperscript{66}
Advanced echocardiographic techniques such as speckle-tracking
imaging which reveals a paradoxical (dyskinetic) positive longitudinal
systolic strain of biventricular mid-apical segments.\textsuperscript{67} Echocardiogra-
phy also identifies covered rupture of the LV free wall\textsuperscript{68} as well as
thrombus formation within a dysfunctional LV apex\textsuperscript{69} or within
left-atrial appendage even in the absence of atrial fibrillation.\textsuperscript{70} Inde-
pendent predictors of adverse outcomes include low left ventricular
ejection fraction (LVEF), increased LV filling pressure, and moderate-
to-severe MR at 4–6 weeks.\textsuperscript{71,72}
At peak, apical and anteroseptal akinesis with basal hyper-
contractility produces near-cavity obliteration.\textsuperscript{73} Typically, LV contractility recovers completely in 4–8 weeks.\textsuperscript{2,74} Some segments of the LV recover earlier than others, displaying increased apical rotation, LV twisting and untwisting and recovered
global longitudinal strain.\textsuperscript{43,75} Resolution of LVOTO and MR\textsuperscript{76} occurs
in parallel with myocardial functional recovery. During TTS recur-
rence, the LV ballooning pattern may resemble the initial event\textsuperscript{77} or
alternatively, manifest as other variants.\textsuperscript{78}

Cardiac computed tomography angiography
In the presence of life-threatening comorbid conditions such as termi-
nal malignancy, intracranial bleeding, advanced age with frailty and
bleeding diathesis, invasive CAG may pose a considerable risk for
complications. In a recent study by Murugiah \textit{et al.}\textsuperscript{79} a substantial pro-
portion of patients with TTS as a secondary diagnosis code did not
undergo CAG. The reasons for not performing CAG were not
described but likely included the mentioned life-threatening comorbid conditions. In such patients, non-invasive CCTA may be an appropriate alternative to CAG. Coronary computed tomography angiography provides information on both coronary artery anatomy and regional LV contraction. Assessment of LV contraction by CCTA requires image acquisition throughout the cardiac cycle and thus higher radiation exposure. In patients with suspected recurrent TTS and a previous CAG, CCTA may be a diagnostic alternative. Furthermore, CCTA may be considered instead of CAG in the following circumstances: in stable patients with low suspicion of ACS, suspected recurrent TTS, and patients with elevation of cardiac biomarkers or ECG changes in association with acute critical illnesses such as sepsis, intracranial disease (e.g. subarachnoid haemorrhage, ischaemic stroke), and other critical conditions known to be complicated by TTS.

Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging cannot be used easily in the acute setting of TTS, but is very useful in the subacute phase. In addition to identification of typical RWMAs, CMR allows precise quantification of RV and LV function, assessment of additional abnormalities/complications (i.e. pericardial and/or pleural effusion, LV and RV thrombi), and characterization of myocardial tissue (i.e. oedema, inflammation, necrosis/fibrosis) (Figure 3C). 80,81 Recently, specific CMR criteria for TTS diagnosis at the time of acute presentation were established which include the combination of typical RWMAs, oedema, and the absence of evidence of irreversible tissue injury [late gadolinium enhancement (LGE)]. 82 While LGE is usually absent and predicts complete normalization of LV function, subtle fibrosis may be present and a sign of worse outcomes. 83–85 In most TTS patients, myocardial oedema is present in regions with abnormal systolic function possibly due to inflammation, increased wall stress and/or transient ischemia 86 and indicative of the extent and severity of tissue injury. 87 CMR is superior to echocardiography for detection of RV involvement 82 including isolated RV TTS 87 which may negatively impact outcome. 88 Importantly, absence of LGE in dysfunctional LV regions allows distinction between TTS and other conditions including ACS (subendocardial or transmural LGE corresponding to a vascular territory) and many cases of acute myocarditis (frequent, but not universal presence of epicardial or ‘patchy’ LGE). Therefore, CMR provides incremental value for the differential diagnosis, and therapeutic decision-making in patients with suspected TTS. 89

Cardiac nuclear imaging
Both single photon emission computed tomography (SPECT, using 201thallium chloride or 99mtechnetium sestamibi) which provides semi-quantitative information and position emission tomography (PET, using 13N-ammonia 82Rubidium) which offers quantitative measurements, have been used in TTS for assessment of perfusion, metabolism, and innervation.

Perfusion imaging
Mild reduction of perfusion in dysfunctional segments using myocardial perfusion scintigraphy has been noted in some studies, while others reported normal perfusion. 90–94 However, ‘myocardial thinning’ in involved segments during the acute phase of TTS may lead to a reduction in isotope counts because of the partial volume effect, which may mimic reduction of perfusion on SPECT, but following correction for this factor on PET, blood flow in the thinned regions (typically in the apex) is indeed maintained, while the normally functioning (basal) segments show hyper-perfusion. 95

Metabolic imaging
The role of metabolic imaging in the clinical setting has not been determined and it has been performed mainly for research purpose of investigating the pathophysiology of TTS, although it can provide additional information about the diseased myocardium. Both SPECT using 123I-β-methyl-iodophenyl pentadecaoncic acid (which reflects fatty-acid) and PET using 18F-flourodeoxyglucose (which reflect glucose utilization) often show reduced metabolic activity in the impaired regions, while myocardial perfusion is often (near) normal. 96,97 An example with apical TTS is shown in Figure 3D, revealing severely reduced 18F-flourodeoxyglucose uptake in the apex despite only slightly reduced perfusion as assessed with 201thallium chloride. 98 Possibly, glucose utilization is disturbed due to insulin resistance as a consequence of high levels of circulating catecholamines. 99

Sympathetic nervous imaging
Myocardial uptake of 123I-metaiodobenzylguanidine (123I-MIBG, imaged with SPECT) reflects myocardial sympathetic innervation 123I-MIBG is reduced for months in dysfunctional segments whereas perfusion is almost normal, consistent with regional disturbance of sympathetic neuronal activity. 100 In the subacute phase of TTS, 123I-MIBG SPECT can be combined with SPECT perfusion imaging to exclude ACS where both perfusion and innervation are reduced. Position emission tomography imaging has also been used in TTS for assessment of cardiac innervation with the use 11C hydroxyephedrine. 101

Complications and outcomes
Although TTS is generally considered a benign disease, contemporary observations show that rates of cardiogenic shock and death are comparable to ACS patients treated according to current guidelines. 103–108 While TTS is a reversible condition, hemodynamic and electrical instability during the acute phase expose patients to the risk of serious adverse in-hospital events which occur in approximately one-fifth of TTS patients (Figure 4). 2 This substantial incidence of life-threatening complications necessitates close monitoring and early intervention in unstable TTS patients with risk stratification at diagnosis allowing triage to appropriate care. 66 Parameters predicting adverse in-hospital outcome include: physical trigger, acute neurologic or psychiatric diseases, initial troponin >10× upper reference limit, and admission LVEF <45%. 2 Furthermore, male patients have an up to three-fold increased rate of death and major adverse cardiac and cerebrovascular events (MACCE) 109 and more often had an underlying critical illness, further contributing to the higher mortality. 2 Sobue et al. 110 demonstrated that physical triggers and male gender are independent risk factors of in-hospital mortality in TTS. Data from the Tokyo Coronary Care Unit Network revealed that high values of BNP and white blood cell counts were also linked to higher rates of in-hospital complications. 111 Complications included cardiac death, pump failure (Killip grade ≥II), sustained ventricular tachycardia or ventricular fibrillation (VT/VF), and advanced atrioventricular block.
In-hospital Complications

**Frequent**
- Acute heart failure (12-45%)
- LVOTO (10-25%)
- Mitral regurgitation (14-25%)
- Cardiogenic shock (6-20%)

**Moderate**
- Atrial fibrillation (5-15%)
- LV-thrombus (2-8%)
- Cardiac arrest (4-8%)
- AV-block ~5%

**Rare**
- Tachyarrhythmia (2-5%)
- Bradycardia (2-5%)
- Torsades-de-poines (2-5%)
- Death (14-5%)
- Ventricular tachycardia/fibrillation ~3%
- Acute ventricular septal defect <1%

**Figure 4** Overview of in-hospital complications according to their prevalence. AV, atrioventricular block; LV, left ventricle; LVOTO, left ventricular outflow tract obstruction.

**Figure 5** Long-term outcome (5-years) of patients with TTS compared to patients with and without CAD (A). Long-term outcome (10-years) of patients with TTS (B). MACCE refers to a composite of death from any cause, recurrence of takotsubo syndrome, stroke or transient ischaemic attack, or myocardial infarction. CAD, coronary artery disease; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; TIA, transient ischaemic attack; TSC, takotsubo stress cardiomyopathy. Reprinted with permission from Tornvall et al. and Templin et al.

In the study by Takashio et al., the magnitude and extent of ST-segment elevation with ECG were found to be independent predictors of in-hospital adverse events. However, those findings were not confirmed by others. Common in-hospital complications include cardiac arrhythmias, LVOTO, cardiogenic shock, ventricular thrombus, pulmonary oedema, ventricular septal defect, and free wall rupture. In addition, to the demographic parameter of age ≥75, echocardiographic parameters that predict adverse in-hospital outcome (acute heart failure, cardiogenic shock, and in-hospital mortality) include LVEF, E/e’ ratio, and reversible moderate to severe MR. However, only reversible moderate to severe MR was an independent predictor when considering cardiogenic shock and death as the composite outcome in this study, in addition to heart rate. Moreover, it has been demonstrated that high heart rate and low systolic blood pressure are associated with increased mortality in TTS. Along with the Charlson comorbidity index and systolic pulmonary artery pressure, RV involvement is an independent predictor of acute heart failure and of a composite endpoint including adverse events, such as acute heart failure, cardiogenic shock, and in-hospital mortality.

Data on long-term survival are scarce. In 2007, Elesber et al. reported that long-term mortality did not differ between a TTS population and an age-, gender-, birth-, year-, and race-matched population. While Sharkey et al. found that all-cause mortality during follow-up exceeded a matched general population with most deaths occurring in the first year. More recently, it has been reported that long-term mortality of patients with TTS is similar to patients with CAD. TTS patient data from the Swedish Angiography and Angioplasty Registry (SCAAR) from 2009 to 2013 were compared to data from patients with and without CAD, and demonstrated that mortality rates for TTS were worse than in patients without CAD and comparable to those of patients with CAD. In the largest TTS registry to date, death rates are estimated to be 5.6% and rate of MACCE 9.9% per-patient year, suggesting that TTS is not a benign disease. A recent study found that patients with the typical TTS type have a comparable outcome to patients presenting with the atypical type even after adjustment for confounders, suggesting that both patient groups should be equally monitored in the long-term. On the other hand, 1-year mortality differs between the two groups, as it is driven by clinical factors including atrial fibrillation, LVEF on admission <45%, and neurologic disorders, rather than by...
TTS type. In a smaller study, predictive factors of long-term mortality in TTS were male sex, Killip class III/IV, and diabetes mellitus. The prognostic role of diabetes mellitus is controversial, as it is postulated that it may exert a protective effect in TTS, given that the prevalence of diabetes mellitus in TTS is lower than expected for an age- and sex-matched population. Some studies, though limited by their population size and experimental design, suggest that patients with diabetes mellitus have a more favourable in-hospital and 1-year outcome.

**Arrhythmias**

Cardiac arrhythmias are important determinants of short-term clinical outcome.

**Ventricular arrhythmias**

Life-threatening ventricular arrhythmias, such as torsades de pointes, VT, or VF occur in 3.0–8.6% and are a frequent cause of death. Life-threatening ventricular arrhythmias occur most often in the subacute phase (i.e. hospital days 2–4) and coincide with anterolateral T-wave inversion and QT-interval prolongation. QTc prolongation at admission occurs in up to half of the patients. Most malignant arrhythmic episodes are associated with a QTc >500 ms, with pause-dependent torsades de pointes degenerating into VF. 

Figure 6 shows a patient with apical ballooning (A). On the third day of hospitalization giant negative T-waves, marked QT prolongation (QTc = 552 ms) and ‘R on T’ premature ventricular beats (B). Telemetry recording of a pause-dependent (‘long-short sequence’) torsade-de-pointes/ventricular fibrillation, which required electrical cardioversion (C). Reprinted with permission from Migliore et al.

Recurrence

Patients who survive the initial event have a second event in approximately 5% of cases, mostly occurring 3 weeks to 3.8 years after the first event. Recurrent TTS afflicts men and women and may occur as a type of acquired long QT syndrome with risk for malignant arrhythmic events. Cardiac magnetic resonance findings reveal an association between transient myocardial oedema, as evidenced by T2-weighted sequences, and dynamic T-wave inversion and QT prolongation. Thus, myocardial oedema may contribute to transmural or regional (i.e. from the apex to the base of the LV) repolarization inhomogeneity. QT prolongation thus reflects the delayed and dispersed ventricular repolarisation that predisposes to local reexcitation and eventually to torsade de pointes or VF.

Rarely, cardiac arrest is the initial presentation of TTS unrelated to QT interval prolongation. The mechanism of these potentially lethal arrhythmias is probably distinct from that encountered during the subacute phase where acute catecholamine toxicity and/or myocardial ischaemia play a primary role. In some cases, TTS may not represent the trigger for tachyarrhythmias, but rather the consequence of the stress of cardiac arrest and/or resuscitation, which may include administration of epinephrine.

**Other cardiac arrhythmias**

New-onset paroxysmal or persistent atrial fibrillation occurs in 4.7%, sinus-node dysfunction in 1.3%, and AV-block in 2.9%, most likely due to neuro-autonomic imbalance, catecholamine stress, and increased vagal tone.

**Figure 6** Arrhythmic complication in takotsubo syndrome. Left ventriculography (antero-posterior view) showing the typical apical ballooning pattern with akinesia of the mid-apical segments and hyperkinesia of the basal segment (A). A 12-lead electrocardiogram recorded at the third day of hospitalization showing giant negative T-waves in leads aVL, L1, L2, aVF and V4–V6, marked QT prolongation (QTc = 552 ms) and ‘R on T’ premature ventricular beats (B). Telemetry recording of a pause-dependent (‘long-short sequence’) torsade-de-pointes/ventricular fibrillation, which required electrical cardioversion (C). Reprinted with permission from Migliore et al.130
at any age including childhood. Both the triggering event and the ballooning pattern may differ during recurrent events. Some have postulated that an index TTS event may protect the affected LV regions from recurrent involvement through a mechanism akin to ischaemic ‘pre-conditioning’. However, detailed review of published cases and clinical experience suggest that there are frequent examples of recurrence in which the ballooning pattern is similar between episodes, thereby making this hypothesis unlikely.

**Therapeutic management**

Guidelines regarding TTS management are lacking as no prospective randomized clinical trials have been performed in this patient population. Therapeutic strategies are therefore based on clinical experience and expert consensus (evidence level C). Table 1 reviews current data on medical management of TTS patients based of retrospective analysis, meta-analysis, and case series. Figure 7 summarizes a proposed therapeutic management approach for patients with TTS.

**Pre-hospital treatment**

As TTS is clinically difficult to distinguish from ACS, upon first presentation patients should be transferred to a cardiology unit with imaging capabilities and a cardiac catheterization laboratory and receive guideline based treatment of ACS, in particular aspirin, heparin, and if required morphine and oxygen. Patients with cardiogenic shock or post cardiac arrest require intensive care. Electrocardiogram monitoring is essential as a prolonged QT-interval may trigger malignant ventricular arrhythmias (torsades de pointes) and AV-block may occur.

**Acute treatment**

Takotsubo syndrome patients with cardiogenic shock, in particular those with apical ballooning should be promptly evaluated for the presence of LVOTO, which occurs in about 20% of cases. This should be performed during angiography with LV pressure recording during careful retraction of the pigtail catheter from the LV apex beyond the aortic valve. Similarly, a pressure gradient can be detected and quantified using Doppler echocardiography using continuous wave Doppler. Particularly, when using catecholamines serial Doppler studies should be considered to detect an evolving pressure gradient. In TTS patients treated with catecholamine drugs a 20% mortality has been reported; although this may represent a selection bias due to the initial presentation of the patients. Recently, it has been suggested that the Ca2+-sensitizer levosimendan could be used safely and effectively in TTS as an alternative inotrope to catecholamine agents. Furthermore, beta-blockers may improve LVOTO, but are contraindicated in acute and severe heart failure with low LVEF, hypotension, and in those with bradycardia. Although evidence is unproven, TTS patients with LVOTO may benefit from the I1 channel inhibitor ivabradine.

As catecholamine levels are elevated in TTS, beta-blockers seem to be reasonable until full recovery of LVEF, but trials supporting this hypothesis are lacking. Animal experiments have shown that apical ballooning is attenuated after administration of drugs with both alpha- and beta-adrenoceptor blocking properties. In an animal model, intravenous metoprolol improved epinephrine-induced apical ballooning. However, due to the potential risk of pause-dependent torsades de pointes, beta-blockers should be used cautiously, especially in patients with bradyarrhythmia and QTc >500 ms. Angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) may potentially facilitate LV recovery. Diuretics are indicated in patients with pulmonary oedema. In addition, nitroglycerin is useful to reduce LV and RV filling pressures and afterload in

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study design</th>
<th>No. of patients</th>
<th>Outcome measures</th>
<th>Follow-up time</th>
<th>Medication</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Santoro et al.</td>
<td>Case series</td>
<td>13</td>
<td>Adverse events</td>
<td>During hospitalization</td>
<td>Levosimendan</td>
<td>Probably beneficial</td>
</tr>
<tr>
<td>Isogi et al.</td>
<td>Retrospective</td>
<td>2110</td>
<td>Mortality</td>
<td>30 days</td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td>Dias et al.</td>
<td>Retrospective</td>
<td>206</td>
<td>MACE</td>
<td>During hospitalization</td>
<td>Antiplatelet</td>
<td>Beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Statins</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACEI</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACEI/ARB</td>
<td>Beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACEI/ARB</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Statins</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACEI/ARB</td>
<td>Beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aspirin</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Statins</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>β-Blockers</td>
<td>Not beneficial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ACEI/ARB</td>
<td>Beneficial</td>
</tr>
</tbody>
</table>

ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; MACE, major adverse cardiac event.

*Reprinted with permission from Kato et al.*
the case of acute heart failure; however, the administration of nitroglycerin in the presence of LVOTO has been found to worsen the pressure gradient and therefore should be avoided in this scenario (see Figure 7).

QT-interval prolonging drugs should be used cautiously in the acute phase because of the risk to induce torsades de pointes or ventricular tachycardia and fibrillation.

Severe LV dysfunction with extended apical ballooning entails the risk of an LV thrombus and subsequent systemic embolism. Although evidence is lacking, anticoagulation with intravenous/subcutaneous heparin would appear to be appropriate in such patients and post-discharge oral anticoagulation or antiplatelet therapy may be considered on an individual, per-patient basis. As LV dysfunction and ECG abnormalities are reversible, an implantable cardioverter-defibrillator for primary or secondary prevention is of uncertain value in TTS patients experiencing malignant ventricular arrhythmias. In case of excessive prolongation of the QT interval or life-threatening ventricular arrhythmias a wearable defibrillator (life vest) could be considered. The residual risk of malignant arrhythmic events after recovery from TTS is unknown. A temporary transvenous pacemaker is appropriate for those with haemodynamically significant bradycardia.

**Long-term treatment**

The use of ACEi or ARB was associated with improved survival at 1-year follow-up even after propensity matching. In contrast, there was no evidence of any survival benefit for the use of beta-blockers. Moreover, one-third of patients experienced a TTS recurrence during beta-blockade suggesting that other receptors such as alpha-receptors, that are more prevalent in the coronary microcirculation, might be involved.

The prevalence of recurrent TTS is relatively low, consequently conducting randomised trials of pharmacological agents to prevent recurrence is challenging. Beta-blocker therapy after hospital discharge does not appear to prevent recurrence, whereas ACEi or ARB are associated with a lower prevalence of recurrence. The significance of this observation remains uncertain and requires validation in other cohorts.

If concomitant coronary atherosclerosis is present, aspirin and statins are appropriate. As TTS mainly occurs in postmenopausal women, hormone replacement therapy may be considered. Concomitant depression or anxiety is common and psychological therapies and rehabilitation may be helpful.

**Figure 7** Management of takotsubo syndrome. ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; AV-block, atrioventricular block; HF, heart failure; IABP, intra-aortic balloon pump; IV, intravenous; LV, left ventricle; LVAD, left ventricular assist device; LVD, left ventricular dysfunction; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; NOAC, novel oral anticoagulant; QTc, QT-time corrected for heart rate; RV, right ventricle; TTS, takotsubo syndrome; VA-ECMO, venoarterial extracorporeal membrane oxygenation; VF, ventricular fibrillation; VT, ventricular tachycardia.
women oestrogen supplementation in those with recurrence is questionable. In an animal model oestrogen supplementation partially attenuated TTS, but chronic oestrogen supplementation after oophorectomy improved the condition. Whether anti-depressants or other psychiatric drugs might provide clinical benefit in such patients is controversial.

Future directions

Over recent years research has shown that TTS is a much more heterogeneous condition than previously thought. Originally believed to be a benign disease, studies have shown that TTS has morbidity and mortality rates that are comparable to those of ACS. TTS can affect many others aside from postmenopausal women with an emotional trigger, as originally described, and can present as an atypical type rather than apical ballooning. Still, there is much more to be uncovered surrounding TTS and the underlying pathophysiology of the syndrome.

Key questions

Many questions need further investigation: Why are women affected predominantly? What is the role of triggering factors in stress responses of the heart? Why do different TTS phenotypes exist? Which patients are vulnerable to TTS or prone to recurrence? Is there a genetic predisposition to TTS? What is the exact pathogenesis of TTS? Are there specific treatment options in the acute stage of this life-threatening syndrome or to prevent recurrence? Additional research needs to be conducted to answer these important questions.

Prospective approaches

The link between the brain and heart seems to play a key role in TTS. Additionally, studies on circulating miRNAs suggest there could be a genetic aspect to the pathophysiology of TTS, and the predominance of female patients suggests that TTS could be related to sex hormones and the endocrine system. Takotsubo syndrome is more than a cardiac disease, and it requires a new and interdisciplinary approach to increase awareness among not only cardiologists, but physicians at large. To establish evidence based strategies for effective TTS treatment, randomized prospective trials will be necessary utilizing a large number of patients from multicentre international consortia.

Funding

J.R.G. has received a research grant “Filling the gap” from the University of Zurich.

Conflict of interest: none declared.

References


